Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
Presented by Mazyar Shadman,(1,2) MD, MPH, and Amy Goodrich,(3) CRNP
From (1)Fred Hutchinson Cancer Research Center, Seattle, Washington; (2)University of Washington, Seattle, Washington; (3)Johns Hopkins School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):312–315 |
© 2020 Harborside™
Mazyar Shadman, MD, MPH, and Amy Goodrich, CRNP, reviewed data regarding the mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL) and strategies for managing adverse events associated with approved therapies for CLL.
For access to the full length article, please sign in